Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERVAL malaria vaccine trial
PACTR202404544467702Phase 3Recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of R21/Matrix-M in malaria (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Prevalence of malaria infection by molecular methods. Started Apr 2024; status: recruiting.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202404544467702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404544467702.